#USA #Watertown #Blood Testing #PlateletDiagnostics #Antiplatelet

PlateletDiagnostics Releases Cutting-Edge Assay for Monitoring Antiplatelet Therapy

PlateletDiagnostics, LLC, based in Watertown, Massachusetts, has made a significant advancement in platelet function testing through the introduction of a novel assay designed to evaluate the effectiveness of antiplatelet therapy. Utilizing a first-of-its-kind approach that monitors the phosphorylation of the platelet protein dynamin-related protein 1 (Drp1), this assay employs a straightforward ELISA format. This innovation presents a practical alternative to traditional tests such as light transmission aggregometry, which often require specialized equipment and expertise, making them less accessible in routine clinical practices.

The newly developed technology leverages insights from a recent publication in Blood, asserting that the phosphorylation of Drp1 serves as a robust foundation for immune-based platelet function assessments. In contrast to existing platelet function assays that typically depend on complex, proprietary systems, PlateletDiagnostics’ method can be performed using standard laboratory ELISA equipment. This allows for the processing of whole blood samples efficiently while integrating seamlessly into existing laboratory workflows. Notably, this innovation enables laboratories to freeze and batch-sample during analysis, significantly minimizing technician time and operational costs compared to other methods.

Benefits of the New Assay

The innovative assay focuses on the dual-site phosphorylation of Drp1, a widely prevalent platelet GTPase whose phosphorylation state varies in reaction to both platelet agonists and antiplatelet medications. During clinical studies of therapies such as aspirin and clopidogrel, the assay demonstrated a comparable performance to traditional aggregometry and point-of-care testing methods. The sensitivity to changes in platelet reactivity underscores the assay's potential in various clinical settings where monitoring platelet function is critical.

Dr. Robert Flaumenhaft, Professor of Medicine at Beth Israel Deaconess Medical Center (BIDMC) and a co-founder of PlateletDiagnostics, emphasized the importance of this advancement, stating, "Antiplatelet medications are essential for millions of patients at risk of heart attacks and strokes, yet we have lacked a cost-effective way to determine if patients are receiving adequate treatment or are resistant to it. Our goal is to render platelet function monitoring accessible for any hospital laboratory, facilitating improved patient care."

Clinical Validation and Future Directions

Clinical proof-of-principle studies have shown that the Drp1 phosphorylation ELISA can accurately track variations in platelet function during the initiation and cessation of antiplatelet therapy. Furthermore, the assay maintains stability under conditions that often compromise other platelet markers, boasting superior dynamic range and signal-to-noise ratios compared to cartridge-based tests. With its low per-test cost and compatibility with current laboratory infrastructures, this technology positions itself as an ideal solution for monitoring larger patient populations undergoing antiplatelet treatment.

As PlateletDiagnostics continues to enhance the assay through further clinical validation, the company is also exploring opportunities for regulatory submission and commercialization. Their proprietary antibodies and assay architecture derive from intellectual property licensed from BIDMC, complemented by additional reagents they have developed to strengthen their competitive edge in the realm of platelet diagnostics.

About PlateletDiagnostics

Founded by experts in platelet biology at Harvard Medical School, PlateletDiagnostics is dedicated to creating next-generation platelet function diagnostics aimed at addressing significant unmet needs in antiplatelet monitoring and testing. Their unique hybrid approach combines immune-based detection techniques with standard laboratory platforms, resulting in sensitive, convenient, and cost-efficient assays that can greatly enhance patient management for those on antiplatelet therapy.